Entrada Therapeutics, Inc.
TRDA
Rank in Stocks
#17066
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to... Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Share Price
$4.69
Last synced: 2026-11-09
Market Cap
$182.61M
Change (1 day)
-4.09%
Change (1 year)
-39.09%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Entrada Therapeutics, Inc. (TRDA)
Category
Healthcare
Operating Margin for Entrada Therapeutics, Inc. (TRDA)
Operating Margin as of November 2026 TTM: -3,767.07%
According to Entrada Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -3,767.07%. At the end of 2025 the company had an operating margin of -613.66%.
Operating Margin history for Entrada Therapeutics, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -3,767.07% | 513.87% |
| 2025 | -613.66% | -2,851.84% |
| 2024 | 22.30% | -1,010.20% |
| 2023 | -2.45% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.01% |
US
|
|
| -149.01% | -99.96% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 31.23% | -100.01% |
BE
|
|
| 29.35% | -100.01% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Entrada Therapeutics, Inc.'s operating margin
What is Entrada Therapeutics, Inc.'s operating margin?
Entrada Therapeutics, Inc.'s operating margin is -3,767.07%, as of Nov 2026.
What was Entrada Therapeutics, Inc.'s operating margin in 2025?
In 2025, Entrada Therapeutics, Inc.'s operating margin was -613.66%, compared with 22.30% in 2024.
How has Entrada Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Entrada Therapeutics, Inc.'s operating margin was highest in 2024 (22.30%) and lowest in 2025 (-613.66%).
How does Entrada Therapeutics, Inc.'s operating margin compare with similar companies?
Entrada Therapeutics, Inc.'s operating margin (-3,767.07%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.